Omega-3 Supplements: Compare EPA, DHA, Fish Oil & Value

Fish oil

The most common omega-3 source, providing EPA and DHA. Concentration varies widely: compare the EPA + DHA per serving, not the total fish oil weight.

Krill oil

Sourced from krill; EPA and DHA are carried in phospholipids rather than triglycerides. A different presentation — compare the declared EPA + DHA amount as always.

Algae oil

A marine microalgae source of EPA and DHA that is vegan. Useful for people who avoid fish; the comparison is still on the declared EPA + DHA per serving.

Cod liver oil

An oil that provides EPA and DHA alongside vitamins A and D. The presence of fat-soluble vitamins means reading the full label matters before comparing.

Triglyceride vs ethyl ester

The chemical form the oil is carried in. Both can deliver EPA and DHA; the form is a processing detail that sits behind the number that actually matters — the declared EPA + DHA amount.

Omega-3 fatty acids are among the most studied nutrients, but “omega-3” is not one homogeneous intervention. Results can differ according to EPA vs DHA, formulation, dose, population, background therapy, and the outcome measured. The summary below orients you using an explicit evidence hierarchy; it is not a treatment or dosing recommendation, and large trials have produced mixed results across outcomes.

What the research landscape looks like

• Evidence hierarchy — why the layer matters

  When reading omega-3 research, distinguish five layers: (1) mechanistic/biological findings (how EPA and DHA act in cells), (2) blood fatty-acid or inflammatory biomarkers (measurable changes in the body), (3) surrogate outcomes such as triglycerides (a risk marker, not a disease event), (4) clinical cardiovascular outcomes such as heart attack, stroke, or death, and (5) formulation- and population-specific evidence. A change in a biomarker or surrogate is not the same as a proven clinical outcome. This hub does not convert biomarker findings into disease-prevention claims.

• Dietary reference values

  EFSA sets an adequate intake of 250–500 mg of EPA+DHA per day for adults. The US has an adequate intake for the plant-derived omega-3 ALA (1.6 g/day for men, 1.1 g/day for women) but no separate RDA for EPA+DHA.

• Marine vs plant sources

  Fish, krill, and algae provide EPA and DHA directly. Plant ALA must be converted, and conversion to EPA and especially DHA is limited. This is why vegan diets often rely on algae oil for direct EPA and DHA.

• Studied outcomes

  Omega-3s have been studied for cardiovascular, cognitive, eye, and inflammatory outcomes. Results vary by population, dose, formulation, and baseline status; no outcome is established here as a supplement effect.

• 2026 moderate-dose EPA+DHA cardiovascular meta-analysis (PMID 42144851)

  A 2026 pooled analysis of 25 RCTs and 25,578 participants found no statistically significant reduction in major adverse cardiovascular events (MACE) and no statistically significant reduction in atrial fibrillation or post-operative atrial fibrillation (AF/POAF) with combined EPA+DHA in the included secondary-prevention and perioperative populations. This result concerns combined EPA+DHA in those specific populations and should NOT be generalized to every omega-3 product, dose, population, or clinical indication. It is one reason broad claims such as “omega-3 prevents heart disease” are too simplistic.

• 2026 formulation-specific high-dose EPA evidence (PMID 42070013)

  A 2026 analysis of formulation-specific cardiovascular outcomes with high-dose eicosapentaenoic acid (EPA) found that high-dose EPA-dominant formulations have a different evidence base from mixed EPA+DHA supplements. This hub does NOT say that prescription or high-dose EPA results prove that ordinary fish-oil supplements prevent cardiovascular events. Formulation identity — EPA-dominant vs mixed EPA+DHA — is part of interpreting the evidence, not a detail to ignore.

• 2026 EPA:DHA ratio meta-analysis (PMID 41568426)

  A 2026 systematic review and meta-analysis of 96 clinical trials indicates that the EPA:DHA ratio and total dose can influence blood fatty-acid profiles and inflammatory biomarkers. These are biomarker and biological-response findings. This hub does NOT convert them into claims that a particular EPA:DHA ratio is clinically superior for preventing disease. A biomarker response is not a proven clinical outcome.

• The central point

  “Omega-3” is not one homogeneous intervention. Results can differ according to EPA vs DHA, formulation, dose, population, background therapy, and the outcome measured. Comparing a high-dose prescription EPA trial with an ordinary mixed EPA+DHA fish-oil supplement is not a like-for-like comparison. Read each study against the specific formulation, dose, and population it actually tested.

• Blood thinners and clotting

  Very high omega-3 intakes can have a mild effect on blood clotting. People on anticoagulant or antiplatelet medication should consult their doctor before high-dose omega-3 supplementation.

• Atrial fibrillation — a dose- and baseline-risk-dependent signal

  A 2026 updated meta-analysis (PMID 42517224; 35 RCTs, 114,592 participants) reported a statistically significant increase in incident atrial fibrillation in the high-cardiovascular-risk / >1.5 g/day EPA+DHA stratum, with a pooled odds ratio of 1.43 (95% CI 1.14–1.79) and an absolute risk difference of approximately 0.8%. The other three dose/risk strata did not show statistically significant increases. This is a dose- and baseline-risk-dependent signal at higher doses — it should NOT be simplified to “omega-3 causes atrial fibrillation.” People with existing atrial fibrillation, a history of AF, or elevated cardiovascular risk should discuss higher-dose omega-3 use with their clinician before starting.

• Marine contaminants

  Marine oils can carry heavy metals and oxidised lipids. Independent testing (e.g. IFOS) and certifications (e.g. Friend of the Sea) are relevant quality signals; HerbParlor records what is reported.

• Fish allergy

  People with fish or shellfish allergy should approach fish- and krill-derived products with care; algae oil is a marine but non-fish alternative worth discussing with a clinician.

No single omega-3 product is “best” for everyone. These neutral criteria help you narrow the field to the products worth comparing side by side. They use only the facts HerbParlor already structures and scores — nothing here is influenced by affiliate availability, commission, or a sponsored ranking.

EPA vs DHA emphasis

Some products lean toward EPA, others toward DHA, and many balance the two. The EPA:DHA split is a label fact, not a quality verdict — decide which split is relevant to your goal, then compare products that disclose it.

Formulation identity — EPA-dominant vs mixed EPA+DHA

High-dose EPA-dominant formulations have a different evidence base from ordinary mixed EPA+DHA fish-oil supplements. Where a label discloses it, note whether the product is EPA-dominant or balanced EPA+DHA, and the EPA:DHA ratio. This hub does NOT treat prescription or high-dose EPA results as proof that ordinary fish-oil supplements prevent cardiovascular events, and does not declare any one formulation universally “best.”

Total EPA+DHA per serving

The combined EPA and DHA amount per serving — not the total fish oil weight — is the single most important number for a fair comparison. A “1,000 mg fish oil” softgel can hold far less EPA+DHA than the headline suggests.

Fish oil concentration

Concentration is the share of the oil that is actually EPA+DHA. Higher concentration means fewer softgels to reach a target EPA+DHA amount. Compare concentration alongside serving size, not in isolation.

Form where documented

Where a label states it, note whether the oil is carried as triglyceride, re-esterified triglyceride, ethyl ester, or phospholipid (krill). HerbParlor records the form as documented; it does not declare one form superior for any outcome.

Serving size

Servings are often one or more softgels. Serving size and servings per container decide how many softgels a day you are comparing and how long a bottle lasts — both feed the standardized value.

Oxidation & testing where documented

Marine oils can oxidize, and independent testing for oxidation and heavy metals is especially relevant. Look for reported third-party verification (e.g. IFOS) and freshness indicators. We record what is reported and never upgrade a claim to independent verification.

Source & provenance

Fish oil, krill oil, and algae oil come from different sources with different supply chains. Provenance — where the oil comes from and who makes it — is part of HerbParlor’s transparency scoring, not a ranking.

Price & value (VitaValue™)

VitaValue™ puts price next to a comparable quantity — cost per 1,000 mg EPA+DHA — so concentration and softgel count cannot disguise the real cost. Use it to compare value only after the criteria above are acceptable to you.

1. 01

   EPA + DHA per serving

   The combined EPA and DHA amount — not the total fish oil weight. This is the single most important number for comparing omega-3 products fairly.

2. 02

   Serving size & servings per container

   Omega-3 servings are often softgels, sometimes several per serving. Servings per container decides how long a bottle lasts and feeds the standardized value.

3. 03

   Concentration & form

   How concentrated the oil is and whether it is carried as triglyceride, re-esterified triglyceride, ethyl ester, or phospholipid (krill). Concentration changes how many softgels you need to reach a given EPA + DHA amount.

4. 04

   Formulation identity & EPA:DHA ratio

   Distinguish EPA-dominant from mixed EPA+DHA products, and note the EPA:DHA ratio where disclosed. High-dose EPA-dominant formulations have a different evidence base from ordinary mixed EPA+DHA fish-oil supplements; this hub does not treat one as universally superior and does not transfer prescription-EPA results to ordinary supplements.

5. 05

   Testing & certifications

   Marine oils are often tested for heavy metals and oxidation. Look for independent verification and certifications such as IFOS or Friend of the Sea. We record what is reported, never upgrading a claim to independent verification.

6. 06

   Standardized value

   VitaValue™ puts price next to a comparable quantity — cost per 1,000 mg EPA + DHA — so concentration and softgel count don’t disguise the real cost.

These are HerbParlor’s existing tools, contextualised for omega-3. Each one turns research into a shortlist you can act on — no sponsored rankings, no hidden ordering.

Every product below is a real, canonical record assessed with the same VitaScore™ rubric. Open any product for the full profile, or compare several side by side.

Editorial explainers that break down the labels, the chemistry, and the comparison framework behind this hub.

• EPA vs DHA: Omega-3 Label Guide

  What EPA and DHA are, how they appear on labels, and why the split matters.

  Read article

• Omega-3 Concentration: Fish Oil vs EPA + DHA

  Why “1,000 mg fish oil” is not the same as 1,000 mg EPA + DHA.

  Read article

• How to Compare Supplements

  The general framework behind every HerbParlor comparison.

  Read article

• How to Verify Third-Party Testing

  What independent verification actually means — and what a claim is not.

  Read article

1. 01

   No sponsored rankings. Ever.

   HerbParlor sells nothing and takes no placement fees. Scores cannot be bought, influenced, or negotiated.

2. 02

   Testing information over label claims

   We note when products report third-party testing, and say so when a product reports none. A manufacturer or retailer claim is never treated as independent verification.

3. 03

   Affiliate-neutral

   Commercial relationships do not influence scores, ordering, or what appears on this hub. Retailer links appear only when verified and are kept separate from editorial analysis.

Is fish oil better than krill or algae oil?

“Better” depends on your goals and is a decision for you and your clinician. Fish, krill, and algae oils are different sources that all provide EPA and DHA in different presentations. This hub helps you compare them on declared EPA + DHA and testing — it does not declare a winner.

What is the difference between fish oil and EPA + DHA?

Fish oil is the total oil weight; EPA and DHA are the specific fatty acids inside it. A 1,000 mg fish oil softgel may contain far less EPA + DHA. Always compare the EPA + DHA amount per serving. Our Omega-3 Concentration article covers it in depth.

How much EPA + DHA is in a serving?

It varies widely between products. Some concentrate EPA + DHA heavily; others list a small amount across several softgels. Read the EPA + DHA per serving and the serving size together rather than the front-of-pack fish oil number.

What testing should I look for in an omega-3 supplement?

Marine oils are often tested for heavy metals and oxidation. Independent verification and certifications such as IFOS or Friend of the Sea are relevant signals. HerbParlor records what a product reports and never treats a brand or retailer claim as independent verification.

Can I take omega-3 with blood thinners?

High-dose EPA+DHA can have a mild effect on blood clotting and may add to the effect of anticoagulant or antiplatelet medication. Typical supplement amounts are usually not a concern, but speak to your doctor before combining high-dose omega-3 with blood thinners.

Is algae omega-3 as good as fish oil?

Algae oil provides direct EPA and DHA and is the common vegan alternative to fish oil. The comparison that matters is the declared EPA+DHA per serving and the testing behind the product — not the source alone. This hub does not declare one source superior for any outcome.

Does all omega-3 have the same cardiovascular evidence?

No. “Omega-3” is not one homogeneous intervention. Results can differ according to EPA vs DHA, formulation, dose, population, background therapy, and the outcome measured. A 2026 pooled analysis of 25 RCTs and 25,578 participants (PMID 42144851) found no statistically significant reduction in major adverse cardiovascular events or atrial fibrillation with combined EPA+DHA in the included secondary-prevention and perioperative populations — a result that should not be generalized to every omega-3 product, dose, or population. This is why broad claims such as “omega-3 prevents heart disease” are too simplistic. Distinguish biomarker and surrogate findings (such as triglyceride changes) from clinical cardiovascular outcomes.

Can high-dose omega-3 increase atrial fibrillation risk?

A dose- and baseline-risk-dependent signal has been reported at higher doses. A 2026 updated meta-analysis (PMID 42517224; 35 RCTs, 114,592 participants) found a statistically significant increase in incident atrial fibrillation in the high-cardiovascular-risk / >1.5 g/day EPA+DHA stratum, with a pooled odds ratio of 1.43 (95% CI 1.14–1.79) and an absolute risk difference of approximately 0.8%; the other three dose/risk strata did not show statistically significant increases. This should NOT be simplified to “omega-3 causes atrial fibrillation.” It is a reason to discuss higher-dose omega-3 use with a clinician if you have existing atrial fibrillation, a history of AF, or elevated cardiovascular risk. Typical supplement amounts are usually not the concern here.

Why do EPA-only and EPA+DHA studies produce different results?

Because they are different interventions. A 2026 analysis of formulation-specific cardiovascular outcomes with high-dose eicosapentaenoic acid (PMID 42070013) found that high-dose EPA-dominant formulations have a different evidence base from mixed EPA+DHA supplements. This hub does NOT say that prescription or high-dose EPA results prove that ordinary fish-oil supplements prevent cardiovascular events. Formulation identity — EPA-dominant vs mixed EPA+DHA, plus the total dose and the population studied — is part of interpreting the evidence, not a detail to ignore.

Does the EPA:DHA ratio matter?

A 2026 systematic review and meta-analysis of 96 clinical trials (PMID 41568426) indicates that the EPA:DHA ratio and total dose can influence blood fatty-acid profiles and inflammatory biomarkers. These are biomarker and biological-response findings, not proof that a particular ratio is clinically superior for preventing disease. A biomarker response is not a proven clinical outcome. Where a label discloses the EPA:DHA ratio, record it as a disclosure fact to compare — this hub does not declare any one ratio universally “best.”